Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 8Sarcoma 1Myeloid 1Lymphoid 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 48fludarabine phosphate 28Filgrastim 27Radiotherapy 26Antilymphocyte Serum 26Busulfan 24Cyclosporine 23Peripheral Blood Stem Cell Transplantation 19Mycophenolic Acid 18Cord Blood Stem Cell Transplantation 17Methylprednisolone 16Methotrexate 16Melphalan 15Etoposide 15Tacrolimus 12Whole-Body Irradiation 11Cytarabine 9Thiotepa 6Vincristine 5Psychiatric Rehabilitation 5sargramostim 4aldesleukin 4Sirolimus 4Leucovorin 4Granulocyte Colony-Stimulating Factor 4fludarabine 3Prednisone 3Early Intervention, Educational 3Daunorubicin 3glucarpidase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × quizartinib × Sarcoma × Clear all
NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡